fbpx

Nyheder

Lundbeckfonden Ventures nyheder

  Lund, Sweden; Lloyd Diamond has been recruited CEO of BONESUPPORT – the Swedish medical technology company with a revolutionary orthobiologic platform for treatment of osteoporotic fractures and deep bone infections. Mr. Diamond replaces Dr. Fredrik Lindberg, the co-founder and present CEO, who will remain in the company as Chief Scientific Officer. By the recruitment...
Bagneux, December 6, 2011 – DBV Technologies announces the arrival of David Schilansky – starting December 19 – as Chief Financial Officer and as such, will supervise all financial activities of the company as well as partnerships and Business Development initiatives. David will be a member of the Executive Committee.“The integration of David Schilansky to...
Cambridge, UK: Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa study of APD209 in cancer cachexia. APD209 comprises a new and patent protected use for an oral combination of two currently marketed drugs and has been designed to increase appetite, muscle...
. Collaboration to leverage Syntaxin and Ipsen’s expertise in the discovery and development of botulinum toxins   Paris (France) and Oxford (UK), 20 October 2011 – Ipsen (Euronext: IPN, ADR: IPSEY) and Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies targeting cell secretion pathways, announced today a global strategic collaboration to explore the discovery...
The Swedish MedTech company BoneSupport is implementing a follow-up share issue with the Danish investment fund Lundbeckfond Ventures. Together with the share issue in June this year, the company has raised totally 170 MSEK during 2011. The company markets CERAMENT T, an injectable biologic that remodels into bone and heals fractures. The raised capital will...
Download press release here: Acacia_Pharma_starts_Phase_II_clinical_trail_f.PDF
The U.S. Food and Drug Administration has granted 510(k) clearance for Asante Solutions' Pearl Insulin Pump. ASANTE_press_release_051711.pdf
DBV demonstrates ability of VIASKIN® to administer allergen via intact skin by targeting dendrictic cells for safe treatment of allergic disease. News_J_Immunol.pdf
1 62 63 64 65 66

Lundbeckfonden Ventures

Nyheder

Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)
13. juli 2020
VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
8. juli 2020
scPharmaceuticals Announces FUROSCIX® NDA Resubmission
3. juli 2020